Starling Oncology launches Nexus platform to simplify prior authorization
Starling Oncology has introduced Nexus, a proprietary platform designed to simplify prior authorization by integrating clinical decision support and utilization management into a seamless digital workflow, enhancing efficiency in oncology treatment processes.
Starling Oncology has developed a proprietary technology platform aimed at streamlining prior authorization, according to an announcement. The company unveiled Starling Oncology Nexus in August.
The platform combines clinical decision support and utilization management in one digital workflow. Key features include:
Timely clinical decision support and evidence-based pathways
Ancillary services like pharmacy and clinical trials incorporated
